SMi presents the launch of Cell & Gene Therapy 2018

SMi Group10 - 11 October, London, UK.
SMi introduces their inaugural event on Cell & Gene Therapy which takes place between the 10th and 11th October 2018, with an interactive pre-conference workshop on the 9th October. Cell and gene therapeutics have revolutionised modern medicine and mark a new generation in biomedical and agricultural sciences. The latest developments in cell and gene therapies and specifically in gene editing, technologies present unlimited research opportunities ranging from novel therapeutic tools to a potential revolution in the field of drug discovery.

This year's event will be led by scientists and clinicians researching, developing and testing new treatments for genetically inherited and acquired diseases using gene delivery technology, stem cell manipulation and DNA repair techniques. The conference will cover all aspects of the subject, including biomedical science principles, molecular basis of disease, current and developing technologies and clinical applications.

The conference will be inviting speakers from global pharmaceutical organisations, leading biotech companies and internationally renowned academic institutions. Expect over 16 presentations and case studies focused on the key aspects of GMP, bioprocessing, regulatory frameworks and new therapeutic developments in in the field of cell and gene.

Hear from our expert speaker panel, bringing you interesting case studies and detailed presentations on new and industry relevant topics, including:

  • Cell Therapy Research
  • Manufacturing Innovation
  • Global Medical Affairs
  • Regulatory Updates
  • GMP and Quality Control
  • Cell and Tissue Therapies (CART therapies, stem cells, cord blood, preclinical and clinical developments)
  • Regenerative Medicine
  • Advanced Therapy Production
  • Gene Therapy Development
  • Clinical Platform Development
  • Manufacturing
  • R&D of Cell and Gene Therapies

Chair for 2018

  • Pamela Tranter, Head of Translational Research Group, UCL

Key speakers include

  • Janet Glassford, Senior Quality Assessor (Biologicals), MHRA
  • Giuseppe Ronzitti, Cell and Gene Therapy Specialist, Genethon
  • Kei Kishimoto, Chief Scientific Officer, SelectaBiosciences
  • Shailesh Gupta, Senior Scientist, AstraZeneca
  • Peggy Sotiropoulou, R&D Manager, Research and Development, Celyad
  • Julie Kerby, Head of Manufacturing Development, Cell and Gene Therapy Catapult
  • Lior Raviv, Vice President, Development, Pluristem
  • Diego Aridgo, R&D Rare Disease Unit Head, Chiesi
  • Mehdi Gasmi, Chief Science and Technology Officer, Adverum Biotech
  • Emanuela Cuomo, Associate Director, Discovery Sciences, Cellular Biology Team, AstraZeneca
  • Yen Choo, Founder and Executive Chairman, Plasticell
  • Ian McKay, Innovation Lead Advanced Therapies, Innovate UK

2018 featured highlights

  • Discuss the challenges of accessing patients with commercial ATMPs
  • Understand the advantages of a risk-based approach to cell and gene therapy manufacturing
  • Hear the MHRA's perspective of UK and EU regulatory affairs regarding ATMPs
  • Explore the unique applications of the CRISPR/Cas9 system for drug development at AstraZeneca
  • Gain insight into GMP Manufacture of plasmid DNA at the NHSBT

View the full agenda online: www.cellandgeneconference.com/wpn

Early-bird rates

  • Register by 31 May and save £400
  • Register by 29th June and save £300
  • Register by 31st August and save £200

About SMi Group

Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at http://www.smi-online.co.uk

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...